Provectus Biopharmaceuticals Announces Acceptance of Abstract for Poster Presentation at 31st SITC Annual Meeting
September 27 2016 - 6:00AM
Business Wire
Poster Presentation of Data on PV-10 in
Treatment of Pancreatic Cancer Accepted
Conference Scheduled for November 9-13, 2016
in National Harbor, Maryland
Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT,
www.provectusbio.com), a clinical-stage oncology and dermatology
biopharmaceutical company ("Provectus" or the "Company”), today
announced that the Society for Immunotherapy of Cancer has accepted
an abstract for a poster presentation related to the use of PV-10,
an investigational ablative immunotherapy under development by
Provectus for solid tumor cancers, in the treatment of pancreatic
cancer.
The abstract, “Intralesional injection with Rose Bengal and
systemic chemotherapy induces anti-tumor immunity in a murine model
of pancreatic cancer,” describes research undertaken at Moffitt
Cancer Center by a team of scientists led by Shari Pilon-Thomas.
The exact time and place of the poster presentation has yet to be
determined. The full abstract will be available on line at
SITCancer.org on November 8 according to conference organizers.
The 31st SITC Annual Meeting and Associated Programs will be
held November 9-13 at the Gaylord National Hotel & Convention
Center in National Harbor, Maryland.
About SITC
The Society for Immunotherapy of Cancer (SITC) is the world’s
leading member-driven organization specifically dedicated to
professionals working in the field of cancer immunology and
immunotherapy. Established in 1984, SITC is a 501(c)(3)
not-for-profit organization with a growing constituency of
academic, government, industry, clinical and basic scientists, and
practitioners from around the world.
Through emphasis on high-caliber scientific meetings; dedication
to education and outreach activities; focus on initiatives of major
importance in the field; and commitment to collaborations with
like-minded domestic and international organizations, government
and regulatory agencies, associations and patient advocacy groups,
SITC brings together all aspects of the cancer immunology and
immunotherapy community.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals is investigating new therapies for
the treatment of skin cancer, liver cancer and breast cancer.
Provectus’ investigational oncology drug, PV-10, is an ablative
immunotherapy under investigation in solid tumor cancers. The
Company has received orphan drug designations from the FDA for its
melanoma and hepatocellular carcinoma indications. PH-10, its
topical investigational drug for dermatology, is undergoing
clinical testing for psoriasis and atopic dermatitis. Provectus has
completed Phase 2 trials of PV-10 as a therapy for metastatic
melanoma, and of PH-10 as a topical treatment for atopic dermatitis
and psoriasis. Information about these and the Company's other
clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information
about Provectus, please visit the Company's website at www.provectusbio.com or contact Porter, LeVay
& Rose, Inc.
FORWARD-LOOKING STATEMENTS: This release contains
"forward-looking statements" as defined under U.S. federal
securities laws. These statements reflect management's current
knowledge, assumptions, beliefs, estimates, and expectations and
express management's current views of future performance, results,
and trends and may be identified by their use of terms such as
"anticipate," "believe," "could," "estimate," "expect," "intend,"
"may," "plan," "predict," "project," "will," and other similar
terms. Forward-looking statements are subject to a number of risks
and uncertainties that could cause our actual results to materially
differ from those described in the forward-looking statements.
Readers should not place undue reliance on forward-looking
statements. Such statements are made as of the date hereof, and we
undertake no obligation to update such statements after this
date.
Risks and uncertainties that could cause our actual results to
materially differ from those described in forward-looking
statements include those discussed in our filings with the
Securities and Exchange Commission (including those described in
Item 1A of our Annual Report on Form 10-K for the year ended
December 31, 2015) and the following:
- our determination, based on guidance
from the FDA, whether to proceed with or without a partner with the
fully enrolled phase 3 trial of PV-10 to treat locally advanced
cutaneous melanoma and the costs associated with such a trial if it
is necessary to complete (versus interim data alone);
- our determination whether to license
PV-10, our investigational drug product for melanoma and other
solid tumors such as cancers of the liver, if such licensure is
appropriate considering the timing and structure of such a license,
or to commercialize PV-10 on our own to treat melanoma and other
solid tumors such as cancers of the liver;
- our ability to license PH-10, our
investigational drug product for dermatology, on the basis of our
phase 2 atopic dermatitis and psoriasis results, which are in the
process of being further developed in conjunction with mechanism of
action studies; and
- our ability to raise additional capital
if we determine to commercialize PV-10 and/or PH-10 on our own,
although our expectation is to be acquired by a prospective
pharmaceutical or biotech concern prior to commercialization.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160927005332/en/
Provectus Biopharmaceuticals, Inc.Peter R. Culpepper,
866-594-5999 #30Interim CEO, COOorPorter, LeVay & Rose,
Inc.Marlon Nurse, 212-564-4700DM, SVP – Investor RelationsorAllison
+ PartnersTodd Aydelotte, 646-428-0644Managing Director – Media
Relations
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Sep 2023 to Sep 2024